Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction
Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao
Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao
View: Text | PDF
Research Article Cardiology

Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction

  • Text
  • PDF
Abstract

Although left ventricular (LV) diastolic dysfunction is often associated with hypertension, little is known regarding its underlying pathophysiological mechanism. Here, we show that the actin cytoskeletal regulator, Rho-associated coiled-coil containing kinase-2 (ROCK2), is a critical mediator of LV diastolic dysfunction. In response to angiotensin II (Ang II), mutant mice with fibroblast-specific deletion of ROCK2 (ROCK2Postn–/–) developed less LV wall thickness and fibrosis, along with improved isovolumetric relaxation. This corresponded with decreased connective tissue growth factor (CTGF) and fibroblast growth factor–2 (FGF2) expression in the hearts of ROCK2Postn–/– mice. Indeed, knockdown of ROCK2 in cardiac fibroblasts leads to decreased expression of CTGF and secretion of FGF2, and cardiomyocytes incubated with conditioned media from ROCK2-knockdown cardiac fibroblasts exhibited less hypertrophic response. In contrast, mutant mice with elevated fibroblast ROCK activity exhibited enhanced Ang II–stimulated cardiac hypertrophy and fibrosis. Clinically, higher leukocyte ROCK2 activity was observed in patients with diastolic dysfunction compared with age- and sex-matched controls, and correlated with higher grades of diastolic dysfunction by echocardiography. These findings indicate that fibroblast ROCK2 is necessary to cause cardiac hypertrophy and fibrosis through the induction CTGF and FGF2, and they suggest that targeting ROCK2 may have therapeutic benefits in patients with LV diastolic dysfunction.

Authors

Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James K. Liao

×

Figure 4

ROCK2 in cardiac fibroblasts is involved in angiotensin II–induced (Ang II–induced) cardiac remodeling through regulation of FGF2, CTGF, and α-SMA expression.

Options: View larger image (or click on image) Download as PowerPoint
ROCK2 in cardiac fibroblasts is involved in angiotensin II–induced (Ang ...
Fibroblast-specific ROCK2-deficient (ROCK2Postn–/–) and littermate control (ROCK2flox/flox) mice (A–H), and fibroblast-specific constitutively active ROCK knock-in (caROCKPostn–/–) and littermate control (caROCKflox/flox) mice (I–N) were treated with saline or Ang II for 4 wk. (A and I) Representative immunoblots of ROCK1, ROCK2, and ROCK activity, as assessed by the ratio of phosphorylated form of the myosin-binding subunit (MBS) to total MBS (p-MBS/t-MBS), in heart tissues from each experimental genotype. (B and C) Quantification of ROCK1 and ROCK2 protein expression, and (D and J) ROCK activity levels by densitometry (n = 4–6 each). (E and K) Representative immunoblots of FGF2, CTGF, and α-SMA in heart tissues from each experimental genotype. (F–H and L–N) Quantification of FGF2, CTGF, and α-SMA protein expression by densitometry (n = 4–6 each). *P < 0.05 vs. saline-treated each genotype. #P < 0.05 vs. Ang II–treated respective controls. Data are expressed as mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s HSD test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts